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The rationale behind this treatment strategy will be 
discussed. A radiotherapy dose-response relationship has 
been observed in prostate cancer, with higher doses 
achieving better local control and survival outcomes. 
However, despite better results, the increased dose results in 
greater rectal and urinary toxicity. Prostate cancer does not 
exist as a homogenous tumour distributed evenly through the 
prostate gland. The disease is often multi-focal and may 
possess varying biological characteristics. It is therefore likely 
that some regions of prostate tumour are more radio-
resistant than other areas. The more resistant regions would 
require a higher dose to achieve the same tumour control 
probability.  mpMRI techniques such as diffusion weighted 
imaging, dynamic contrast enhanced MRI, intrinsic 
susceptibility weighted MRI and spectroscopy can produce 
valid biomarkers for characteristics such as hypoxia, cellular 
proliferation, vascularity and clonogen density. The ability to 
incorporate this information into radiotherapy planning and 
to selectively increase the dose administered to these 
relatively resistant regions should achieve better tumour 
control without the degree of toxicity produced by whole 
gland dose escalation. 
In addition, the technical challenges that focussed dose 
escalation poses to the operator and planning team will be 
explored in this talk. For example, the implantation process 
itself causes geometric deformation of the gland, making 
fusion of any pre-implantation image difficult and error-
prone. Also, the implant itself may change the tumour micro-
environment. A significant drop in blood flow, associated 
with an increase in tumour hypoxia may be caused by the 
trauma of needle insertion. 
The optimum dosimetric model to achieve dose escalation to 
the boost volume whilst maintaining a lower dose to the 
remaining gland by individualizing the needle positions will 
be discussed and early clinical evidence for focussed dose 
boosting using High Dose Rate brachytherapy will be 
presented.  
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Introduction: Focal radiotherapy treatment procedures play 
increasingly important role in function and organ 
preservation treatment techniques. Focal and differential 
radiotherapy already has an established role in partial organ 
treatments for other tumor sites, e.g., partial breast 
irradiation in low-risk breast cancer. An alternative to 
traditional whole gland treatments, focal radiotherapy may 
be of benefit for both primary tumor as well as locally 
recurrent disease. 
Material and Methods: Review of the current literature on 
the topic including patient selection, preliminary toxicity and 
outcome data as well as a technical overview on treatment 
delivery techniques. 
Results: Partial organ treatment in early prostate cancer is 
now technically feasible. To date only small and generally 
monoinstitutional series have been published.Early feasibility 
and toxicity data encouraging and demonstrate potential 
advantages for the role of focal brachytherapy. 
Summary: Brachytherapy is the ideal choice for small volume 
partial organ treatments in low-risk prostate cancer. To date, 
only preliminary results are available (HDR/LDR) and no large 
cohort comparative results are published. Further 
prospective and comparative controlled investigations with 
larger cohorts are needed.  
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Purpose/Objective: Outstanding long-term biochemical 
control rates and local tumor control rates have been 
reported after permanent low-dose-rate brachytherapy (LDR-
BT) in low-risk prostate cancer patients. However, 
treatment-related side effects such as irritative and 
obstructive urethral symptoms have also been reported. We 
investigated in this study a differential target and dose 
prescription concept for prostate LDR-BT including a re-
distribution of dose according to risk of local failure and 
treatment related morbidity. 
Materials and Methods: Our study included 15 consecutive 
prostate cancer patients treated with low-dose-rate 
brachytherapy (LDR-BT) using 125-iodine seeds. Multi-
parametric MRI sequences were acquired prior to LDR-BT for 
gross tumor volume (GTV) delineation. The prostate gland 
(CTVProstate) and organs at risk (OARs) were defined on trans-
rectal US images, acquired during LDR-BT. The GTV structure 
was transferred to US images after MRI-US image registration. 
A high-risk target volume (CTVHR= GTV + 5 mm margin) was 
defined. The CTVProstate was treated as an intermediate-risk 
target volume. Two dose plans were made: Plan1 involved 
redistribution of dose with a de-escalated dose of minimum 
125 Gy to CTVProstate and a dose escalation to 250 Gy to CTVHR, 
if consistent with OAR constraints; Plan2 involved the 
standard clinical dose of minimum 145 Gy to CTVProstate. DVH 
parameters were converted to equivalent dose in 2 Gy 
fractions (EQD2) for targets and OARs. 
Results: Dose redistribution Plan1 resulted in an increased 
GTV-D90 by a median of 40 Gy (range, 2 - 130 Gy) and an 
increased CTVHR-D90 by a median of 15 Gy (range, 1 - 68 Gy) 
as compared to standard clinical planning (Plan2) (p<0.001) 
(Figure 1). The urethral D10 and D30 decreased by a median 
of 13 Gy (range, -1 - 43 Gy) and 14 Gy (range, 6 - 36 Gy), 
respectively while the bladder neck D10 and D30 decreased 
by a median of 25 Gy (range, 1 - 39 Gy) and 21 Gy (range, 5 - 
32 Gy), respectively (p<0.001). The rectal D2.0cm3 had a 
median decrease of 6 Gy (ranging from a 13 Gy decrease to a 
1 Gy increase) (p<0.001), while the rectal D0.1cm3 had a 
median increase of 2 Gy (ranging from a 46 Gy decrease to a 
32 Gy increase) (p=0.45). 
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Figure 1. Panels A+C abd B+D illustrate respective dose 
distribution for Plan1 and Plan2 for one patient case. 
 
 
Conclusions: A differential target and dose prescription 
strategy was technically feasible with LDR-BT seed planning 
and resulted in a significant dose reduction to both urethra 
and bladder neck, as compared to standard clinical dose 
planning.  
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Purpose/Objective: Focal brachytherapy (BT) is investigated 
as an alternative to whole gland BT for salvage treatment of 
recurrent prostate cancer to potentially improve functional 
outcome while maintaining cancer control. The aim of this 
study was to evaluate feasibility and toxicity of such 
treatment using high-dose-rate (HDR) brachytherapy. 
Materials and Methods: Seventeen patients were included in 
this prospective pilot study from May 2012 to July 2014. All 
the patients had received primary external beam 
radiotherapy with total dose of 70-78 Gy and experienced 
biochemical failure according to Phoenix criteria. Inclusion 
criteria were PSA <10 at inclusion, no detectable metastases 
on FACBC-PET-CT or pelvic MRI and a visible relapse tumour 
on FACBC-PET-CT or multiparametric MRI. All patients 
performed a bone marrow aspiration to assess the presence 
of micrometastatic disease in bone marrow. The salvage BT 
was delivered in 3 fractions with planning aim of 10 Gy to the 
tumour volume. For each fraction, separated by two weeks, 
the needles were applied using transrectal ultrasound (US) 
guidance. The gross tumour volume (GTV) was delineated in 
the US images based the on pre-treatment MR and FACBC-
PET-CT imaging. The urethra and the rectum wall were also 
delineated. Intra-operative treatment planning optimisation 
was performed for each fraction. Dose-volume-histogram 
parameters were found and 2Gy-eqivalent (EQD2) total dose 
were calculated using the LQ-model. The toxicity was scored 
using the EORTC/RTOG scale. 
Results: The median age of the patients was 69 years (range: 
60-75). Table 1 summarises the key dosimetry parameters 
achieved for this study. The GTV was in average 24% the 
whole prostate gland (range: 6-56). For all the patients the 
GTV D90 was above the total planning aim of 78 Gy (EQD2, 
α/β = 3). 
 
 
 
There were a significant correlation between the number of 
needles used and the volume of the GTV (R2 = 0.39, p<0.001). 
However, no correlation was found between the number of 
needles and the GTV D90, or between the volume of the GTV 
and the GTV D90. 
The median follow-up was 9 months (range: 3-21). Three 
patients (16%) experienced grade 2 genitourinary (GU) or 
gastrointestinal (GI) symptoms (GU urge, pollakisuria and 
urine leakage). Only one patient reported grade 3 
pollakisuria. In Figure 1 the GU and GI toxicity grades are 
plotted against the total EQD2 dose for rectum D2cm3 and 
urethra D0.1cm3.  
 
Conclusions: Our results suggest that focal HDR salvage 
brachytherapy is feasible with a GTV D90 above the planning 
aim for all the patients. The toxicity was acceptable; 
however, longer follow up is needed.  
  
 
Poster Discussion: Intrafraction and interfraction 
management  
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Purpose/Objective: Respiratory motion cause significant 
dose errors in IMPT for lung cancer patients due to induced 
variations in range and the interplay effect. The aim of this 
study was to investigate the relation between the respiratory 
amplitude and the dose errors due to the these effects.  
Materials and Methods: Intensity-modulated proton therapy 
(IMPT) plans with co-planar beam directions perpendicular to 
